Original news and analysis on international IP policy
Raising awareness, creating effective stewardship, national action plans on antimicrobial resistance, building trust and getting onto the agenda of the G20 are critical to fostering access and appropriate use of antibiotics, according to speakers at yesterday’s joint technical symposium on antimicrobial resistance (AMR).
While the issue of antimicrobial resistance has arrived in high-level discussions, and there is a consensus that the problem must be tackled one way or another to avoid slipping back into a pre-antibiotic era, some voices are highlighting the need to remember that other health issues remain unmet, and access to medicines is still an acute problem.
The issue of antimicrobial resistance has been in the spotlight in recent months as a growing awareness of the threat it represents for humanity has pushed discussions at the multilateral level. This week, the World Health Organization, World Intellectual Property Organization and World Trade Organization organised a symposium on the subject. Speakers discussed needs and potential solutions.
Under its new health emergencies program, the World Health Organization is setting up an improved structure for global health emergencies like the Ebola outbreak. But the UN agency is also opening itself up to a role as partnership broker to ensure the world has what it needs when the emergencies arise. And in doing so, WHO is trying to ensure that it remains the central player in global policy discussions and is not just an emergency response unit.
Resistance to antibiotics by bacteria has been steadily growing and is now considered as a major threat to global public health, with some catastrophic projections of millions of death and billions of dollars in economic impact. The World Trade Organization, World Health Organization and World Intellectual Property Organization today are holding a joint technical symposium on antimicrobial resistance, and how to encourage innovation, appropriate use of antibiotics, and wide access to treatments and diagnostics.
The group of experts tasked to monitor the World Health Organization pandemic influenza framework met this week with discussions on the partnership contributions that industry is expected to provide to the system, and how influenza viruses' genetic sequence data should be handled in the context of the framework.
The World Health Organization pandemic influenza framework advisory group is meeting this week, behind closed doors. A consultation is expected to take place on 20 October with stakeholders, and an information session has been organised on 21 October on the work of the advisory group, but no press is allowed in either meeting nor able to obtain any information about any aspect of the week’s events.
The term “Open” in science is all the rage these days.
A new database was launched this week to facilitate navigation through the patent field and increase transparency surrounding the patent status of medicines and licences.
As autumn rolled in, two United Nations agencies chose global figures to help them with their missions, another has a new website, and changed heads, while non-governmental organisations, law offices, and industry also saw numerous changes at management level.
Initiating a new partnership today, global health initiative UNITAID and the non-profit FIND began a project that will work towards the improvement, affordability and availability of diagnostics and treatments for the hepatitis C virus (HCV).
A conference on clinical drug trials held today shed a harsh light on the availability and honesty of clinical trial reports. Many factors concur to possible distortion of results, speakers said, calling for more stringent obligations to provide all data for analysis. They also noted legislative efforts to tackle the issue. Speakers also pointed out a growing trend for pharmaceutical companies to conduct clinical trials in developing countries.